The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor

Sponsor
Kanuni Sultan Suleyman Training and Research Hospital
Study ID
NCT07358754
Status
Recruiting
Apply to this trial

Conditions

  • Fibromyalgia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Accepted

Interventions

  • No Intervention (Observational Study) — OTHER
    This is an observational study with no therapeutic or diagnostic intervention. Participants will undergo a single-time-point clinical assessment and venous blood sampling for biomarker measurement only.

Study Details

Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified. Brain-derived neurotrophic factor (BDNF) and S100B protein have been suggested to play roles in neuroinflammation and central pain processing. This observational, cross-sectional study aims to evaluate serum S100B and BDNF levels in patients with fibromyalgia and to investigate their relationship with central sensitization and sleep quality. Serum biomarker levels and clinical assessment scales will be compared between patients with fibromyalgia and healthy controls.

Key Dates

First listed
Jan 22, 2026
Start date
Feb 1, 2026
Status verified
Apr 2026
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Fibromyalgia Group
    Female patients aged 18-50 years diagnosed with fibromyalgia according to the 2016 American College of Rheumatology criteria.
  • Arm: Healthy Control Group
    Age- and sex-matched healthy female volunteers without fibromyalgia or chronic widespread pain.

Primary Outcome Measure

Association between serum S100B and serum BDNF [ Time Frame: Baseline ]

Central Contacts

Related Studies